After Kenvue (KVUE) shares fell 9.3% on Friday after the WSJ reported that Health Secretary Robert F. Kennedy Jr. plans to release a report suggesting concerns linking Tylenol use in utero to the development of autism and ADHD, BofA analyst Anna Lizzul noted that the company’s new CEO and CFO took the opportunity in August to reset expectations at earnings and sees its lowered 2025 guidance as “achievable.” Given the current valuation discount to the average of HPC peers, the firm reiterates its Buy rating and $25 price target as it sees a widening discount offering “a particularly attractive entry point.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Kenvue, Inc. Hold Rating: Concerns Over Tylenol-Autism Link and Strategic Uncertainty
- Kenvue Stock (KVUE) Plunges on Report Linking Tylenol to Autism
- HHS says report of Tylenol, autism link ‘speculation,’ Bloomberg reports
- RBC says scientific link between Tylenol and autism unproven in court
- Kenvue extends selloff after WSJ report, shares down 16% to $17.33